Congratulations to Positrigo on successfully closing an oversubscribed CHF 7 million financing round—a significant achievement that reflects strong investor confidence in your innovative NeuroLF brain imaging platform. The support from HealthCap, Navivo, and existing investors underscores the importance of making advanced diagnostic tools more accessible, particularly in addressing the global challenge of Alzheimer's disease.
The appointment of new board members, including experienced leaders like Max Odlander and Didier Deltort, further strengthens the company's strategic position as it scales up production and commercialization. This marks a pivotal step forward in advancing the future of neurological diagnostics. Well done to the entire team at Positrigo.
Our team here at Sino HK Capital is honored to have served as the exclusive financial advisor in support of this important achievement.
For more details: https://www.positrigo.com/positrigo-closes-financing-round-and-appoints-new-board-members/
About Positrigo:
Positrigo is a pioneer in nuclear medical imaging technologies. Headquartered in Zurich, Switzerland, the medical device company was founded in 2018 as a spin-off of ETH Zurich. Positrigo’s technology, development, clinical testing and commercialization has been supported by various private investors, the Swiss government and the European Innovation Council. NeuroLF – the company’s first device – is an ultra-compact brain Positron Emission Tomography (PET) scanner which has applications in the assessment of causes of dementias, such as Alzheimer’s disease and other brain related disorders. This award-winning product is the first device of its to gain market clearance in the US and EU.